Menopausal symptoms in women treated for breast cancer: The prevalence and severity of symptoms and their perceived effects on quality of life

Climacteric

Volumn 9, Issue 1, 2006, Pages 49-58

  Gupta, P ^a   Sturdee, D W ^a   Palin, S L ^b,c   Majumder, K ^a   Fear, R ^a   Marshall, T ^b   Paterson, I ^a  

^a SOLIHULL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Breast cancer treatment; Hot flushes; Menopausal symptoms; Quality of life

Indexed keywords

ALPHA TOCOPHEROL; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CIMICIFUGA RACEMOSA EXTRACT; CLONIDINE; HERBACEOUS AGENT; MEGESTROL ACETATE; PRIMROSE OIL; TAMOXIFEN; TIBOLONE; VENLAFAXINE;

ADULT; ARTICLE; AWARENESS; BREAST CANCER; CHEMOTHERAPY; CORRELATION ANALYSIS; DIET THERAPY; DISEASE SEVERITY; ESTROGEN DEFICIENCY; FEMALE; HEALTH SURVEY; HOT FLUSH; HUMAN; INFORMATION; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; PREVALENCE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; SOYBEAN; SWEAT; VAGINAL DRYNESS; VASOMOTOR REFLEX;

ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; ENGLAND; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 31544446637     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130500487224     Document Type: Article

References (34)

1. Buckley MM, Goa KL. Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 1989;37:451-90
2. Jones KL, Buzdar AU. A review of adjuvant hormonal therapy in breast cancer. Endocrine-Related Cancer 2004;11:391-406
3. Ganz PA. Impact of tamoxifen adjuvant therapy on symptoms, functioning and quality of life. J Natl Cancer Inst Monogr 2001;30:130-4
4. Carpenter JS, Andrykowski MA, Cordova M, et al. Hot flashes in postmenopausal women treated for breast carcinoma. Prevalence, severity, correlates, management, and relation to quality of life. Cancer 1998;82:1682-91
5. Harris PF, Remington PL, Trentham-Dietz A, et al. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage 2002;23:501-9
6. Canney PA, Hatton MQF. The prevalence of menopausal symptoms in patients treated for breast cancer. Clin Oncol 1994;6:297-9
7. Hunter M, Battersby R, Whitehead M. Relationship between psychological symptoms, somatic complaints and menopausal complaints and menopausal status. Maturitas 1986;8:217-28
8. ATAC Trialists' group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2
9. Decensi A, Bonanni B, Guerrieri-Gonzaga A, et al. Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 1998;90:1461-7
10. Loprinzi CL, Kugler JW, Sloan JL, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-63
11. Stearns V, Beebe KL, Iyengar M, et al. Paroxetine controlled release in the treatment of menopausal hot flashes. A randomized controlled trial. JAMA 2003;289:2827-34
12. Moyad MA. Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: re evaluating the existing indirect data from studies of breast cancer and postmenopausal women. Urology 2002;59(4 Suppl 1):20-33
13. Daly E, Gray A, Barlow D, et al. Measuring the impact of menopausal symptoms on quality of life. BMJ 1993;307:836-40
14. Schneider HPG, Heinemann LAJ, Rosemeier HP, et al. The Menopause Rating Scale (MRS): comparison with Kupperman index and quality-of-life scale SF-36. Climacteric 2000;3:50-8
15. O'Dea I, Hunter MS, Anjos S. Life satisfaction and health-related quality of life (SF-36) of middle-aged men and women. Climacteric 1999;2:131-40
16. McKinlay SM, Jefferys M. The menopausal syndrome. Br J Prevent Soc Med 1974;28:108-15
17. Neugarten BL, Kraines RJ. 'Menopausal symptoms' in women of various ages. Psychosom Med 1965;27:266-73
18. Fenlon D. Menopause: a problem for breast cancer patients. Eur J Cancer Care 1995;4:166-72
19. Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with history of breast cancer and attitude towards hormone replacement therapy. J Clin Oncol 1995;13:2737-44
20. Ganz PA. Impact of tamoxifen adjuvant therapy on symptoms, functioning and quality of life. J Natl Cancer Inst Monogr 2001;30:130-4
21. Nicol-Smith L. Causality, menopause, and depression: a critical review of the literature. BMJ 1996;313:1229-32
22. Pearce J, Hawton K, Blake F. Psychological and sexual symptoms associated with the menopause and the effects of hormone replacement therapy. Br J Psychiatry 1995;167:163-73
23. Avis NE, Crawford S, Stellato R, et al. Longitudinal study of hormone levels and depression among women transitioning through menopause. Climacteric 2001;4:243-9
24. Joffe H, Hall JE, Soares CN, et al. Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause 2002;9:392-8
25. Burgess C, Cornelius V, Love S, et al. Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ 2005;330:342-4
26. Hay AG, Bancroft J, Johnstone EC. Affective symptoms in women attending a menopause clinic. Br J Psychiatry 1994;164:513-6
27. Sloan JA, Loprinzi CL, Kuross SA, et al. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol 1998;16:3662-73
28. Hlatky MA, Boothroyd D, Vittinghoff E, et al. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/progestin Replacement Study (HERS) trial. JAMA 2002;287:591-7
29. Holmberg L, Anderson H, for the HABIT steering and data monitoring committees. HABIT (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped. Lancet 2004;363:453-5
30. Dew J, Eden J, Beller E, et al. A cohort study of hormone replacement therapy given to women previously treated for breast cancer. Climacteric 1998;1:137-42
31. Dew JE, Wren BG, Eden JA. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study. Climacteric 2002;5:151-5
32. Durna EM, Crowe SM, Leader LR, Eden JA. Quality of life of breast cancer survivors: the impact of hormonal replacement therapy. Climacteric 2002;5:266-76
33. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 2003;6:45-52
34. Farish E, Barnes JF, O'Donoghue F, et al. The role of megestrol acetate as an alternative to conventional hormone replacement therapy. Climacteric 2000;3:125-34